| |  Online-Ressource |
|---|
| Verfasst von: | Rohde, David [VerfasserIn]  |
|---|
| | Brinks, Henriette [VerfasserIn] |
|---|
| | Ritterhoff, Julia [VerfasserIn] |
|---|
| | Qui, Gang [VerfasserIn] |
|---|
| | Ren, Shumei [VerfasserIn] |
|---|
| | Most, Patrick [VerfasserIn] |
|---|
| Titel: | S100A1 gene therapy for heart failure |
|---|
| Titelzusatz: | A novel strategy on the verge of clinical trials |
|---|
| Verf.angabe: | David Rohde, Henriette Brinks, Julia Ritterhoff, Gang Qui, Shumei Ren, Patrick Most |
|---|
| Jahr: | 2011 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Available online 20 August 2010 ; Gesehen am 19.09.2022 |
|---|
| Titel Quelle: | Enthalten in: Journal of molecular and cellular cardiology |
|---|
| Ort Quelle: | New York, NY [u.a.] : Elsevier, 1970 |
|---|
| Jahr Quelle: | 2011 |
|---|
| Band/Heft Quelle: | 50(2011), 5, Seite 777-784 |
|---|
| ISSN Quelle: | 1095-8584 |
|---|
| Abstract: | Representing the common endpoint of various cardiovascular disorders, heart failure (HF) shows a dramatically growing prevalence. As currently available therapeutic strategies are not capable of terminating the progress of the disease, HF is still associated with a poor clinical prognosis. Among the underlying molecular mechanisms, the loss of cardiomyocyte Ca2+ cycling integrity plays a key role in the pathophysiological development and progression of the disease. The cardiomyocyte EF-hand Ca2+ sensor protein S100A1 emerged as a regulator both of sarcoplasmic reticulum (SR), sarcomere and mitochondrial function implicating a significant role in cardiac physiology and dysfunction. In this review, we aim to recapitulate the translation of S100A1-based investigation from first clinical observations over basic research experiments back to a near-clinical setting on the verge of clinical trials today. We also address needs for further developments towards “second-generation” gene therapy and discuss the therapeutic potential of S100A1 gene therapy for HF as a promising novel strategy for future cardiologists. This article is part of a Special Section entitled “Special Section: Cardiovascular Gene Therapy”. |
|---|
| DOI: | doi:10.1016/j.yjmcc.2010.08.012 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/j.yjmcc.2010.08.012 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0022282810002993 |
|---|
| | DOI: https://doi.org/10.1016/j.yjmcc.2010.08.012 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Calcium |
|---|
| | Gene therapy |
|---|
| | Heart failure |
|---|
| | Mitochondria |
|---|
| | Myofilaments |
|---|
| | Reticulum |
|---|
| | S100A1 |
|---|
| | Sarcoplasmic |
|---|
| K10plus-PPN: | 1816934895 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
S100A1 gene therapy for heart failure / Rohde, David [VerfasserIn]; 2011 (Online-Ressource)
